ASH 2023 | High-dose chemotherapy and autoSCT for R/R primary mediastinal large B-cell lymphoma
Yago Nieto, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of high-dose chemotherapy and autologous stem cell transplantation (autoSCT) for relapsed/refractory (R/R) primary mediastinal large B-cell lymphoma (PMBCL), a rare type of diffuse large B-cell lymphoma (DLBCL). A single-center experience found that patients treated with rituximab-vorinostat/gemcitabine/busulfan/melphalan (R-vorinostat/GemBuMel) had superior event-free survival (EFS) and overall survival (OS) to those receiving rituximab-BEAM (carmustine, etoposide, cytarabine, melphalan) conditioning prior to autoSCT. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Affimed, Astra Zeneca, Secura Bio
